This article, published in Morbidity and Mortality Weekly Report, reports on the revision that the US Food and Drug Administration has approved for the prescribing information and patient labeling for rotavirus vaccines manufactured by GlaxoSmithKline Biologicals (Rotarix) and Merck & Co. (RotaTeq) to include history of intussusception as a contraindication. This change is based on new research regarding the potential increased risk for intussusception following rotavirus vaccine administration.

Author(s): US Centers for Disease Control and Prevention

Published: 2011

Resource types: Newsletter/article

Diseases: Rotavirus

Topics: Introduction and service delivery; Vaccine safety; Disease/vaccine specific information

Regions: North America and Europe